Literature DB >> 28627278

Methotrexate for the treatment of pediatric alopecia areata.

Erin T Landis1, Rita O Pichardo-Geisinger1.   

Abstract

PURPOSE: Alopecia areata is a form of nonscarring hair loss that occurs in pediatric and adult patients, with presentation varying from round or ovoid patches of alopecia to alopecia totalis or universalis. While frustrating for patients, it can also be frustrating for clinicians to treat, as there is no definitive treatment. Dermatologists are very familiar with the use of methotrexate for psoriasis and other inflammatory skin diseases, and this medication is generally well tolerated in children. MATERIALS/
METHODS: This study presents a case series reviewing the efficacy of methotrexate in our pediatric patients with alopecia areata, making use of a retrospective chart review design from 2011 to 2016.
RESULTS: In this data set, 8/14 subjects (57%) experienced good regrowth with methotrexate, while 3/14 (21%) had a response that could not be assessed due to loss to follow-up or premature discontinuation of the medication. No cases discontinued the medication due to recognized methotrexate side effects.
CONCLUSIONS: This review suggests methotrexate is a generally safe and often effective medication in pediatric alopecia areata.

Entities:  

Keywords:  Alopecia areata; hair loss; methotrexate; pediatric dermatology

Mesh:

Substances:

Year:  2017        PMID: 28627278     DOI: 10.1080/09546634.2017.1341608

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  2 in total

1.  Efficacy and Tolerability of Methotrexate in the Treatment of Severe Paediatric Alopecia Areata.

Authors:  Henrietta Albela; Sabeera Begum; Ai Leen Wee; Nirmala Ponnuthurai; Kin Fon Leong
Journal:  Skin Appendage Disord       Date:  2022-01-10

Review 2.  Treatment of pediatric alopecia areata: A systematic review.

Authors:  Virginia R Barton; Atrin Toussi; Smita Awasthi; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2021-04-30       Impact factor: 15.487

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.